Magnesium L-threonate,
does it really help with Improved deep sleep, rapid-eye-movement sleep, and daytime function in adults with nonclinical sleep dissatisfaction?
research showsThe sleep and daytime-function claim for magnesium L-threonate is rated at the low end of C. In an 80-person, 21-day double-blind randomized trial, Oura deep-sleep and rapid-eye-movement-sleep scores and some daytime activity, readiness, post-awakening behavior, energy, and productivity measures improved versus placebo. Placebo deterioration contributed to some contrasts, many outcomes were tested, and sleep stages came from a wearable proprietary algorithm rather than polysomnography. In a 100-person, six-week trial, sleep-related impairment improved, but sleep disturbance, restorative sleep, wellbeing, and all objective Oura sleep outcomes did not differ between groups. Both trials used the single branded Magtein ingredient and received AIDP or Threotech industry funding, so conflict and the manufacturer-supported ceiling support C with 44 points.
ads claimMarketing expands animal brain-magnesium findings and wearable scores from one trial into a proven brain-specific magnesium that reliably increases deep and rapid-eye-movement sleep. Human evidence consists of two small industry-funded trials of the same branded ingredient, and objective sleep was null in the second trial.
Useful facts when choosing a product
- Magtein is a branded magnesium L-threonate ingredient, and the current sleep-trial findings apply directly to that ingredient and the tested doses.
- The 21-day trial used 1 g/day, while the six-week trial used 2 g/day and delivered 145 mg of elemental magnesium.
- Wearable deep- and rapid-eye-movement-sleep values are estimates derived from physiological signals and proprietary algorithms, not the same measurement as clinical polysomnography.
- Results from generic magnesium supplements or other magnesium salts cannot automatically be transferred to Magtein, nor can Magtein results be transferred to other salts.
Chamgap Semantic Classification Code
Candidate index · review held
S.magnesium-l-threonate.UNK.deep-sleep-rapid-eye-movement-sleep-and-daytime-function-with-nonclinical-sleep-dissatisfaction.improve.placeboSupplements and nutraceuticals > Magnesium L-threonate > Unknown > deep sleep, rapid-eye-movement sleep, and daytime function with nonclinical sleep dissatisfaction > Improvement claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Hausenblas and colleagues assigned 80 adults aged 35 to 55 with self-reported sleep problems to 1 g/day of Magtein or placebo for 21 days. Between-group interactions favored Magtein for Oura deep-sleep score, P<0.001, rapid-eye-movement-sleep score, P=0.020, light-sleep time, P=0.006, several activity and readiness measures, post-awakening behavior, energy, and productivity. A correction disclosed retrospective registration in 2024 and that AIDP commissioned and funded the study, owned patents, and paid or retained three authors. Lopresti and Smith assigned 100 adults aged 18 to 45 to 2 g/day for six weeks. Sleep-related impairment improved, P=0.043, but sleep disturbance, P=0.316, restorative sleep, P=0.439, wellbeing, P=0.436, and all Oura sleep outcomes were null. Threotech provided funding, intellectual property, design conceptualization, and product.
Why this is classified as C (44)
Some objective estimates and subjective outcomes were positive in the 80-person trial, but all objective sleep outcomes were null in the 100-person trial and both studies were industry-funded tests of the same branded ingredient. Small samples, conflicting findings, multiple endpoints, wearable surrogates, and the manufacturer-supported ceiling give C with 44 points. Diarrhea, abdominal discomfort, and magnesium accumulation with impaired kidney function are separate safety issues.
Counterpoint. Anyone trying it should check elemental magnesium and overlap with other supplements and consider causes such as sleep apnea, depression, anxiety, medicines, and caffeine. Persistent insomnia warrants clinical assessment regardless of supplement response.
Rejudgment record. New verdict — Accepted positive deep-sleep, rapid-eye-movement-sleep, and daytime-function signals in an 80-person industry-funded trial, but applied the rule ②-b ceiling of C because a 100-person industry-funded trial found objective sleep null and the evidence relies on wearable surrogates, multiple endpoints, retrospective registration, and the same branded Magtein ingredient
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved deep sleep | C | The first trial's Oura deep-sleep score was positive, but all objective sleep outcomes were null in the follow-up trial and polysomnographic confirmation is absent. |
| Improved rapid-eye-movement sleep | C | A positive Oura rapid-eye-movement score in the first trial is limited by sample size, multiple testing, industry support, and null follow-up objective sleep. |
| Improved daytime function and vitality | C | Energy, productivity, and activity signals in the first trial and improved sleep-related impairment in the follow-up are selective and entirely industry-funded. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Hausenblas HA et al. 2024 | Randomized double-blind placebo-controlled parallel trial | 80 adults with self-reported sleep problems; 76 analyzed | Commissioned and funded by patent-holding AIDP; Magtein supplied by Threotech; conflicts disclosed in a correction | Oura sleep, activity, and readiness plus subjective sleep, mood, energy, and productivity | Deep-sleep score, P<0.001, rapid-eye-movement-sleep score, P=0.020, light-sleep time, P=0.006, and some daytime outcomes were positive, with multiple endpoints and placebo-group deterioration. | Key early positive product trial |
| Lopresti AL and Smith SJ. 2026 | Randomized double-blind placebo-controlled parallel trial | 100 adults dissatisfied with sleep | Threotech provided funding, intellectual property, design conceptualization, and investigational product | Primary cognition outcome, subjective sleep and wellbeing, and Oura sleep, heart rate, and heart-rate variability | Only sleep-related impairment was positive at P=0.043; sleep disturbance, restorative sleep, wellbeing, and all Oura sleep outcomes were null. | Follow-up conflicting evidence with null objective sleep |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-22).
Final verification and publication gate: Codex · Evidence date: 2026-07-22 · Corrections: none
Cite this verdict
[Chamgap] Magnesium L-threonate x improved deep sleep, rapid-eye-movement sleep, and daytime function — Evidence Grade C·44. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/sleep/magnesium-l-threonate-sleep-stages-daytime-function/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.